Trial Profile
Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Anakinra (Primary) ; Etanercept (Primary) ; Liraglutide (Primary) ; Plerixafor (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 24 Jul 2023 Planned primary completion date changed from 10 Jul 2023 to 10 Jul 2024.
- 18 Jul 2023 Planned primary completion date changed from 30 Dec 2025 to 10 Jul 2023.
- 06 Jul 2022 Status changed from recruiting to active, no longer recruiting.